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WC1E 6AU, UK
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c The Maxillofacial Unit, St George’s Hospital, Blackshaw Road, London, SW17 0QT UKReceived 20 June 2005; accepted 21 June 2005Summary There is conflicting evidence in the literature as to the role of positron
emission tomography (PET) using 18-fluoro-2-deoxyglucose (FDG) in the staging and
management of mucosa associated lymphoid tissue (MALT) lymphoma. We report a
case of FDG avid MALT lymphoma of the parotid gland supporting the recently pub-
lished series in the literature and suggest that whole body FDG-PET could be a useful
technique in some patients with MALT lymphoma. Detection of FDG avid disease
would spare patients several invasive investigations and reduce the radiation burden
of staging. Where FDG avid disease is detected, PET could play an important role in
follow up as well. A negative scan, whilst unhelpful for staging, comes at an accept-
able radiation dose in the context of defining the primary disease.c 2005 Elsevier Ltd. All rights reserved.
KEYWORDS
PET;
MALT lymphoma;
Parotid Gland1
d
1
dIntroduction
Positron emission tomography (PET) has been in
existence for in excess of 20 years. More latterly
it has found an increasing role as an aid to the diag-
nosis, prognosis, and monitoring of a variety of dif-
ferent malignancies. PET provides functional
imaging of tumour physiology, and as such comple-741-9409/$ - see front matter c 2005 Elsevier Ltd. All rights reser
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ossy).ments, or in specific circumstances supersedes
standard structural imaging modalities.MALT lymphoma
MALT lymphomas are B-cell lymphomas of the non-
Hodgkin’s type. They are rated as extranodal mar-
ginal zone lymphomas of MALT-type in the Revised
European-American classification of lymphoid neo-
plasms (REAL) classification.1 The MALT lymphomas
may be classified as low and/or high-grade histo-
logically. They may arise in the aerodigestive tract,
lung, oropharynx, breast, lacrimal and salivaryved.
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multi-focal. A consistent feature in their genesis
appears to be a background of chronic antigenic
stimulation, perhaps best exemplified by the rela-
tionship between Helicobacter pylori and gastric
MALT lymphoma.2
MALT lymphomas appear to be derived from the
‘centrocyte-like’ cells that surround the B-cell fol-
licles. The tumour cells resemble these cells and
share their phenotypic and functional properties.
One of these properties is to enable cells to infil-
trate epithelium and in doing so form one of the
characteristic features of these tumours, the lym-
phoepithelial lesion.Figure 1 MRI (coronal section) demonstrating ill
defined mass within the left parotid gland. No evidence
of tumour in the right parotid gland.Case report
A 49-year-old Vietnamese lady was referred to the
Maxillofacial Unit with a painless right-sided facial
swelling. This had been present for 2 months but
had not changed in size over that period. Examina-
tion revealed a firm, 2 · 3 cm non-tender mass in
the right pre-auricular area. There was no deficit
in facial nerve function and no associated cervical
lymphadenopathy. Intra-oral examination was
unremarkable and specifically there was no bulging
of the right oropharynx. Past medical history was
unremarkable. Ultrasonography (US) demonstrated
a well-circumscribed 2 cm diameter solid mass
within the right parotid gland, consistent with be-
nign parotid neoplasia. Fine needle aspiration
cytology (FNAC) showed features consistent with
benign reactive hyperplasia but could not rule out
lymphoma. Routine haematological screening and
chest radiography were unremarkable.
In view of the size of the lesion and the failure of
FNAC to exclude neoplasia the patient underwent a
right superficial parotidectomy. Histology revealed
a 2 · 1 · 1 cm mass, the features of which were
consistent with B-cell MALT Lymphoma.
Following this diagnosis further staging investi-
gations including CT of the head and neck, chest,
abdomen and pelvis, a bone marrow aspirate and
trephine, were all negative.
The patient was reviewed regularly on the onco-
logy clinic and initially remained disease free.
However, 18 months after surgery a 1-cm mobile
non-tender swelling was noted in the left pre-auric-
ular region. Magnetic resonance imaging (MRI)
demonstrated a poorly defined, non-homogenous
mass within the left parotid gland but no evidence
of recurrent tumour in the residual right parotid
gland (Fig. 1). FNAC of the lesion on this occasion
revealed features consistent with MALT lymphoma.The patient was restaged according to our stan-
dard protocol outlined above. In addition whole
body FDG-PET was performed which showed two
foci of increased glucose activity in the left parotid
region (Fig. 2). Tracer uptake in the right parotid
gland and the rest of the body was normal.
The patient subsequently underwent a left
superficial parotidectomy. Histology of the lesion
revealed a dense infiltrate of centrocyte-like cells,
scattered blasts and plasma cells. A pale collar of
centrocyte-like cells with B-cell morphology sur-
rounded the numerous lymphoepithelial lesions.
These neoplastic cells expressed CD20, IgM and
showed kappa light chain restriction. These fea-
tures are consistent with a diagnosis of extranodal
marginal zone B-cell MALT lymphoma (Fig. 3). The
patient remains well 15 months following her most
recent procedure.Discussion
FDG-PET is a useful imaging tool in a wide variety
of cancers including malignant melanoma, lung,
colorectal, breast, cervical, oesophageal and head
and neck cancer.3 In addition the majority of lym-
phomas are FDG avid.4
Figure 2 F-18-FDG whole body PET demonstrating multi-focal MALT lymphoma in the left parotid gland.
Figure 3 Photomicrograph of a section through the left
parotid gland demonstrating features of MALT lymphoma
(hematoxylin and eosin stain).
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regarding the utility of FDG PET in MALT lym-
phoma. Hoffman et al. 5 in 1999 reported a series
of 10 patients with MALT lymphoma who under-
went FDG-PET scanning and reported no focal tra-
cer uptake in any of the 10 patients. In 2003 the
same group published their findings from a series
of 21 patients with marginal zone lymphomas. 14
out of 21 had extranodal marginal zone lymphoma
of the MALT type.6 Once again, they reported that
none of the 14 patients had focal tracer uptake in
their respective tumour sites. In 2002, two case re-ports were published that showed focal tracer
uptake in lung MALT lymphomas7,8 and more
recently in 2005, Beal et al.9 reported a series of
42 patients with MALT lymphoma. In 34 of 42 pa-
tients, there was FDG avidity demonstrating that
MALT lymphomas can be detected in the majority
of patients.
In all these series, only two cases of parotid
MALT lymphoma were reported. Only one was
FDG avid in the most recent series.9 Our case is
the only other reported case of FDG avid MALT lym-
phoma of the parotid gland.
Staging in MALT lymphoma is complex involving a
number of invasive investigations because of the
wide distribution of MALT within the body, the pos-
sibility of multi-focal disease and the propensity for
distant spread. Indeed comprehensive staging com-
monly includes ophthalmologic evaluation, panen-
doscopy with multiple biopsies, CT of the thorax
and abdomen and bone marrow biopsy. Although
this battery of investigations may seem formidable
it has until now been the only way to stage patients
and determine appropriate management.
The potential advantages of FDG-PET in this re-
gard are fourfold. Firstly it can stage the whole
body in a single investigation in less than 1 h, sec-
ondly it can detect low volume disease (<1 cm3),
thirdly it can assess extranodal sites such as the
liver and spleen better than CT, and finally, the
radiation dose to the patient is less with PET than
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30 mSv).Conclusion
The use of FDG-PET in staging and management of
MALT lymphoma remains unclear. More reports are
being published in the literature that support the
role of FDG-PET as a valuable imaging and staging
tool. We report a case of FDG avid MALT lymphoma
of the parotid gland. Detection of FDG avid disease
would spare patients several invasive investigations
whilst reducing the radiation burden of current
staging protocols. A negative scan, whilst unhelpful
for staging, comes at an acceptable radiation dose
in the context of defining the primary disease. Fur-
ther studies of FDG-PET in MALT lymphoma are
clearly required to clarify its role in investigating
and monitoring such disease. However, our case re-
port and other recent series support the idea that
such investigative effort is warranted.
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